Details

Autor(en) / Beteiligte

• Agulnik, Mark

Titel

New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma

Ist Teil von

• Cancer, 2012-03, Vol.118 (6), p.1486-1497

Ort / Verlag

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• Although sarcomas account for a small portion of solid malignancies, currently, there are few treatment options for sarcomas, particularly for advanced disease. The mammalian target of rapamycin (mTOR), a serine‐threonine protein kinase in the phosphatidylinositol 3‐kinase/serine/threonine protein kinase Akt signaling pathway, has an important role in the regulation of protein synthesis, cell proliferation, angiogenesis, and metabolism. Alterations of the mTOR signaling pathway are common in malignancies, including several types of sarcoma. Therefore, mTOR is a potentially important therapeutic target in these diseases. Rapamycin and its analogs (rapalogs) are effective anticancer agents in a broad range of preclinical models. Clinical trials with these agents alone and in combination with other anticancer agents, including chemotherapy and targeted therapies, have demonstrated potential clinical benefit in several types of sarcoma. The evidence from both preclinical and clinical studies supports further study of mTOR‐targeting rapalogs in the treatment of various subtypes of sarcoma. Cancer 2011;. © 2011 American Cancer Society. Clinical trials with the mammalian target of rapamycin (mTOR), alone and in combination with other anticancer agents, including chemotherapy and targeted therapies, have demonstrated potential clinical benefit in several subtypes of sarcoma. The current results indicate that evidence from both preclinical and clinical studies support further study of mTOR‐targeting rapalogs in the treatment of sarcoma.